Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

June 1, 2027

Conditions
NSCLCNeoadjuvant ImmunotherapyLow Dose RadiotherapySintilimab
Interventions
RADIATION

Experimental

Radiation: 30Gy/15F Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2,D1 or 130mg/m2,D1,8 IV Q3W

DRUG

Active comparator

Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2,D1 or 130mg/m2,D1,8 IV Q3W

Trial Locations (1)

230001

RECRUITING

Anhui Provincial Cancer Hospital, Hefei

All Listed Sponsors
lead

Anhui Provincial Cancer Hospital

OTHER